Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma

Charles W Cummings, Steven M. Larson, Robert A. Dobie, Ernest A. Weymuller, Thomas G. Rudd, Augusto Merello

Research output: Contribution to journalArticle


Critical assessment of head and neck cancer with respect to staging has, on occasion, been disappointingly ineffective. We have attempted to correlate the incidence of measure-able uptake of cobalt 57 tagged bleomycin by primary squamous cell carcinoma and metastatic cervical lymph nodes. Forty-six cases have been evaluated with respect to histo-pathological confirmation of the suspected metastatic disease. We have found that this diagnostic measure increases our acumen in staging of head and neck cancer. The relevance of the Co-Bleo scans as a diagnostic aid is reported in 46 cases. Malignant tumors greater than 2 cm in size appear to demonstrate active uptake of the imaging agent. Small tumor size and excess background radioactivity contribute to the false-negatives (17%). Inflammatory conditions or benign tumors of the salivary apparatus may result in minimal uptake, thus, a false-positive result (10%). An increase in the radioactivity of the Co-Bleo may enhance the benefits of this procedure in the search for an undiagnosed primary, as well as undiagnosed local or distant metastases.

Original languageEnglish (US)
Pages (from-to)529-537
Number of pages9
Issue number4
Publication statusPublished - 1981
Externally publishedYes


ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Cummings, C. W., Larson, S. M., Dobie, R. A., Weymuller, E. A., Rudd, T. G., & Merello, A. (1981). Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. Laryngoscope, 91(4), 529-537.